BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD)...
ZICC: The Farm with Wings
BEIJING, Jan. 16, 2025 /PRNewswire/ -- In Ningbo, Zhejiang, David W. Ferguson, honorary chief English editor at Foreign Languages Press, met Jin Lishen, the local Fruit and Vegetable King, and included Jin's story in his new book China's Development...
Global Times: Xi stresses adherence to 'one country, two systems' as Macao celebrates 25th anniversary of return to motherland
BEIJING, Dec. 21, 2024 /PRNewswire/ -- Chinese President Xi Jinping stressed on Friday the long-term adherence to "one country, two systems" as Macao celebrates a quarter-century of transformative success since its return to the motherland. At a...